Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biogipuzkoa (36)

2024

  1. Nueva era terapéutica para el ataque de migraña con los recientemente aprobados anticuerpos monoclonales, ditanes y gepantes

    Revista de neurologia, Vol. 78, Núm. 2, pp. 47-57

2022

  1. Cutaneous Allodynia in Migraine: A Narrative Review

    Frontiers in Neurology, Vol. 12

  2. Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism

    Brain, Vol. 145, Núm. 6, pp. 2092-2107

2020

  1. Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats (Psychopharmacology, (2020), 237, 8, (2419-2431), 10.1007/s00213-020-05544-6)

    Psychopharmacology

  2. Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders

    Parkinsonism and Related Disorders, Vol. 70, pp. 74-81

  3. Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease

    Movement Disorders, Vol. 35, Núm. 2, pp. 316-325

  4. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats

    Psychopharmacology, Vol. 237, Núm. 8, pp. 2419-2431

  5. [18F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 11, pp. 2602-2612

2019

  1. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 10, pp. 2065-2076

  2. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease

    Neurobiology of Aging, Vol. 75, pp. 126-135

2018

  1. Mitochondrial activity in the frontal cortex area 8 and angular gyrus in Parkinson's disease and Parkinson's disease with dementia

    Brain Pathology, Vol. 28, Núm. 1, pp. 43-57

  2. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study

    Movement Disorders, Vol. 33, Núm. 11, pp. 1809-1813

  3. Transcriptomic integration of D4R and MOR signaling in the rat caudate putamen

    Scientific Reports, Vol. 8, Núm. 1

  4. Using Kinect to classify Parkinson's disease stages related to severity of gait impairment

    BMC Bioinformatics, Vol. 19, Núm. 1

2017

  1. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update

    The Lancet Neurology, Vol. 16, Núm. 3, pp. 238-250

  2. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study

    Movement Disorders, Vol. 32, Núm. 7, pp. 1066-1073

2016

  1. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Science Translational Medicine, Vol. 8, Núm. 341

  2. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 6, pp. 861-881

  3. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2R1441G Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 3, pp. 335-343

  4. Genetic Mutation Analysis of Parkinson’s Disease Patients Using Multigene Next-Generation Sequencing Panels

    Molecular Diagnosis and Therapy, Vol. 20, Núm. 5, pp. 481-491